Preventing sexually transmitted infections: Back to basics

Journal of Clinical Investigation

Volumn 121, Issue 12, 2011, Pages 4580-4583

  Rompalo, Anne ^a,b  

^a PERDANA UNIVERSITY   (Malaysia)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MACROLIDE; PENICILLIN G; TETRACYCLINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL OVERGROWTH; CLINICAL FEATURE; DISEASE ASSOCIATION; FEVER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LYMPHADENOPATHY; MALAISE; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PELVIC INFLAMMATORY DISEASE; PRIMARY INFECTION; PRIORITY JOURNAL; RASH; REVIEW; SECONDARY INFECTION; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREPONEMA PALLIDUM; UTERINE CERVIX CANCER; VACCINE FAILURE; VAGINA DISCHARGE; VAGINITIS; VIRUS SHEDDING; VIRUS TRANSMISSION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; FEMALE; FORECASTING; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HUMANS; MALE; METAGENOME; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEXUALLY TRANSMITTED DISEASES; SYPHILIS; VAGINA;

EID: 84055193968     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61592     Document Type: Review

References (36)

1. World Health Organization. The Global Elimination Of Congenital Syphilis: Rationale And Strategy For Action. Geneva, Switzerland: WHO Press; 2007.
2. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009;22(1):87-91.
3. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Surveillance 2009. Atlanta, Georgia, USA: US Department of Health and Human Services; 2010.
4. Ho EL, Lukehart SA. Syphilis: using modern approaches to understand an old disease. J Clin Invest. 2011;121(12):4584-4592.
5. Fraser CM, et al. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science. 1998;281(5375):375-388. (Pubitemid 28340777)
6. Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. JAMA. 2003; 290(11):1510-1514. (Pubitemid 37430408)
7. Riviere GR, et al. Identification of spirochetes related to Treponema pallidum in necrotizing ulcerative gingivitis and chronic periodontitis. N Engl J Med. 1991;325(8):539-543.
8. LaFond RE, Molini BJ, Van Voorhis WC, Lukehart SA. Antigenic variation of TprK V regions abrogates specific antibody binding in syphilis. Infect Immun. 2006;74(11):6244-6251. (Pubitemid 44657404)
9. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.
10. Lukehart SA, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351(2):154-158.
11. Matejkova P, et al. Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of Treponema pallidum subsp. pallidum. J Med Microbiol. 2009; 58(pt 6):832-836.
12. Zhou P, et al. Azithromycin treatment failure among primary and secondary syphilis patients in Shanghai. Sex Transm Dis. 2010;37(11):726-729.
13. Florindo C, Reigado V, Gomes JP, Azevedo J, Santo I, Borrego MJ. Molecular typing of treponema pallidum clinical strains from Lisbon, Portugal. J Clin Microbiol. 2008;46(11):3802-3803.
14. Walboomers JM, et al. Humanpapilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19. (Pubitemid 29406813)
15. Romanowski B. Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Hum Vaccin. 2011;7(2):161-169.
16. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011;121(12):4593-4599.
17. Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis. 2009;36(11):696-703.
18. Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest. 2011;121(12):4600-4609.
19. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86(10):805-812.
20. Wald A, Link K. Risk of human immunodeficiency virus infection in herpessimplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185(1):45-52. (Pubitemid 34043015)
21. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73-83. (Pubitemid 41818117)
22. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995; 333(12):770-775.
23. Crespi CM, Cumberland WG, Wald A, Corey L, Blower S. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect. 2007;83(5):359-364. (Pubitemid 47242482)
24. Tronstein E, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011; 305(14):1441-1449.
25. Schiffer JT, et al. Frequent release of low amounts of herpes simplex virus from neurons:results of a mathematical model. Sci Transl Med. 2009; 1(7):7ra16.
26. Posavad CM, et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol. 2010;184(6):3250-3259.
27. Roest RW, et al. Genotypic analysis of sequential genital herpes simplex virus type 1 (HSV-1) isolates of patients with recurrent HSV-1 associated genital herpes. J Med Virol. 2004;73(4):601-604. (Pubitemid 38857212)
28. Roest RW, Maertzdorf J, Kant M, van der Meijden WI, Osterhaus AD, Verjans GM. High incidence of genotypic variance between sequential herpes simplex virus type 2 isolates from HIV-1-seropositive patients with recurrent genital herpes. J Infect Dis. 2006;194(8):1115-1118. (Pubitemid 44547651)
29. Stanberry LR, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002; 347(21):1652-1661. (Pubitemid 35340783)
30. Cohen J. Painful failure of promising genital herpes vaccine. Science. 2010;330(6002):304-304.
31. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-4617.
32. Hillier SL, Holmes KK, Marrazzo JM. Bacterial vaginosis. In: Holmes KK, et al., eds. Sexually Transmitted Diseases. New York, New York, USA: McGraw-Hill, Health Professions Division; 2008:737-768.
33. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22. (Pubitemid 13221599)
34. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29(2):297-301.
35. World Health Organization, Department of Reproductive Health and Research. Prevalence And Incidence Of Selected Sexually Transmitted Infections. Geneva, Switzerland: WHO Press; 2011.
36. Toskin I. Sexually transmitted infections epidemiology. Paper presented at: Training Course in Sexual and Reproductive Health Research, July 8, 2011; Geneva, Switzerland. http://www.gfmer.ch/SRH-Course-2011/sti/STI-Epidemiology- Toskin-2011.htm. Accessed October 26, 2011.